Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.22    
    

 
 

AMENDMENT NO. 1 TO PATENT LICENSE AGREEMENT    
    

        This AMENDMENT No. 1 to PATENT LICENSE AGREEMENT ("Amendment") is made and entered into as of the 28th day of February 2002, to be effective march
31, 2002, by and between NOMOS CORPORATION ("Licensee") and the Board of Regents ("Board") of the University of Texas System, collectively referred to as "the Parties." 

RECITALS  

        A.    Board
and Licensee entered into a Patent License Agreement having an effective date of October 21, 1998 ("License"). 

        B.    Board
and Licensee wish to amend the terms of the License as set forth below, to change the minimum royalties, the due date of the minimum royalties, and to extend the
term of the License. 

        C.    As
a condition of enactment of this Amendment No. 1. All royalties and minimum payments which are owed under the term specified in Section 5.1 of the
License Agreement dated October 21, 1998 shall be paid. 

        NOW,
THEREFORE, it is hereby agreed as follows: 

        1.     Section 5.1
of the License shall be revised to read in its entirety as follows: 

        "5.1 In
Consideration of rights granted by Board to Licensee under this Agreement, Licensee will pay Board the following: 

        a.     A
royalty, payable quarterly, beginning march 31, 2002, of $6,000 for all new Sales, in conjunction with the Sale of a Peacock(R)System, of a Licensed Product as defined
in the License, manual or otherwise; 

        b.     A
minimum annual royalty of %50,000 due within 30 days of March 31st of each year, beginning March 31, 2003." 

        2.     Section 5.5
shall be revised to read in its entirety as follows: 

        "5.5 All
amounts payable here by Licensee must be paid in United States funds without deductions for taxes, assessments, fees, or charges of any kind, except as required by
applicable law. Checks must be payable to Board of Regents, The University of Texas System, and shall be delivered to: 

Victor
M. Saenz 

Office of Technology Ventures

San Antonio Technology Center

3463 Magic Drive, Suite 350

San Antonio, Texas 78229" 

        3.     Sections
6.2 and 6.3 of the License shall be deleted in their entirety. 

1

 

        4.     Section 15.2
of the License shall be revised to read as follows: 

        "15.2   Any
notice required by this Agreement must be given by prepaid, first class, certified mail, return receipt requested, addressed in the case of
University to: 

The
University of Texas Health Science Center at San Antonio

Office of Technology Ventures

San Antonio Technology Center

3463 Magic Drive, Suite 350

San Antonio, Texas 78229

ATTENTION: Alan H. Dean, 

Director of Technology Development and Commercialization 

FAX: (210) 567-1337 

PHONE: (210) 567-0150 

With
copies to: 

Board
of Regents

The University of Texas System

201 West 7th Street 

Austin, Texas 78701 

ATTENTION: Office of General Counsel 

FAX: (512) 4494523 

PHONE: (512) 499-4462 

Or
in the case of Licensee to: 

NOMOS
Corporation 

2591 Wexford Bayne Road 

Sewickley, PA 15143 

ATTENTION: Fred Marroni, 

Vice President, Engineering and Development

FAX: (724) 934-5488

PHONE: (724) 934-8200 

Or
other addresses as may be given from time to time under the terms of this notice provision." 

        5.     Section 6.1
of the License shall be revises to read as follows: 

        "6.1 The
term of this Agreement shall be two (2) years from the Effective Date of March 31, 2002." 

        6.     Except
as provided in this Amendment, all other terms, conditions, and provisions of the License shall continue in full force and effect as provided therein. 

SIGNATURES ON THE FOLLOWING PAGE.  

2

 

        IN
WITNESS THEREOF, the Parties have entered into this Amendment effect as of the date set forth above. 

	BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM	 	NOMOS CORPORATION
	

By:	

/s/ FRANCISCO G. CIGARROA
 Francisco G. Cigarroa, M.D.
 President

The University of Texas Health Science Center at San Antonio	
 	

By:	

/s/ JOHN W. MANZETTI
 John W. Manzetti
 CEO and President
	

Date:	

4-2-02	
 	

Date:	

March 20, 2002
	

Approved as to Form:	
 	

 	

 
	

By:	

/s/ ALAN H. DEAN
 Alan H. Dean, M.B.A.
 Office of Technology Ventures	
 	

 	

 
	

Date:	

3/26/02	
 	

 	

 
	

Approved as to Content:	
 	

 	

 
	

By:	

/s/ H. STEVE LYNCH
 H. Steve Lynch
 Executive Vice President for Business Affairs	
 	

 	

 
	

Date:	

4-2-2002	
 	

 	

 

3

QuickLinks

Exhibit 10.22

AMENDMENT NO. 1 TO PATENT LICENSE AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.23    
    

 
 

LIMITED EXCLUSIVE
  PATENT AND COPYRIGHT LICENSE AGREEMENT
  
    FOR
  
    PEREGRINE(TM) DOSE CALCULATION SYSTEM
  FOR RADIATION TREATMENT PLANNING
  
    BETWEEN
  
    THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA
  
    AND
  
    NOMOS CORPORATION
  
    LLNL CASE NO. TL-1613-99
  
    LAWRENCE LIVERMORE NATIONAL LABORATORY
  UNIVERSITY OF CALIFORNIA
  P.O. BOX 808, L-795, LIVERMORE, CA 94551

INDUSTRIAL PARTNERSHIPS AND COMMERCIALIZATION
  
    JULY 1999    

 
 

TABLE OF CONTENTS    
    

	1.	 	BACKGROUND	 	1
	2.	 	DEFINITIONS	 	2
	3.	 	LICENSE GRANT	 	3
	4.	 	SUBLICENSING RIGHTS AND OBLIGATIONS	 	4
	5.	 	FEES, ROYALTIES AND PAYMENTS	 	4
	6.	 	PERFORMANCE OBLIGATIONS	 	5
	7.	 	PROGRESS AND ROYALTY REPORTS	 	6
	8.	 	BOOKS AND RECORDS	 	8
	9.	 	TERM	 	8
	10.	 	TERMINATION AND DISPOSITION OF LICENSED PRODUCTS	 	9
	11.	 	PATENT PROSECUTION AND MAINTENANCE	 	9
	12.	 	PATENT AND COPYRIGHT INFRINGEMENT	 	10
	13.	 	USE OF NAMES AND TRADEMARKS	 	10
	14.	 	LIMITED WARRANTY	 	11
	15.	 	INDEMNIFICATION	 	12
	16.	 	INSURANCE	 	12
	17.	 	WAIVER	 	12
	18.	 	ASSIGNABILITY	 	13
	19.	 	LATE PAYMENTS	 	13
	20.	 	NOTICES	 	13
	21.	 	DISPUTES AND GOVERNING LAWS	 	13
	22.	 	PATENT MARKING	 	13
	23.	 	COPYRIGHT MARKING	 	14
	24.	 	GOVERNMENT APPROVAL OR REGISTRATION	 	14
	25.	 	EXPORT CONTROL LAWS	 	14
	26.	 	FORCE MAJEURE	 	14
	27.	 	UNITED STATES PREFERENCE	 	14
	28.	 	PROPRIETARY INFORMATION	 	15
	29.	 	MISCELLANEOUS	 	15
	EXHIBIT A—LICENSED PATENTS AND LICENSED COPYRIGHTS	 	16
	EXHIBIT B—RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS	 	20
	EXHIBIT C—FEES AND ROYALTIES	 	22
	EXHIBIT D—MUTUAL NONDISCLOSURE AGREEMENT	 	23

  

 
 

LIMITED EXCLUSIVE PATENT AND COPYRIGHT LICENSE AGREEMENT
  FOR PEREGRINE(TM) DOSE CALCULATION SYSTEM
  FOR RADIATION TREATMENT PLANNING    
    

This
Agreement is effective on the Effective Date by and between The Regents of the University of California ("THE REGENTS"), under its U.S. Department of Energy Contract
No. W-7405-ENG-48 to manage and operate Lawrence Livermore National Laboratory ("LLNL"), and NOMOS Corporation, a Delaware corporation having
its principal place of business at 2591 Wexford-Bayne Road, Sewickley, PA 15143. THE REGENTS is a corporation organized and existing under the laws of the State of California, with its principal
office at 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200. THE REGENTS and NOMOS Corporation are referred to jointly as "Parties." 

	1.
	BACKGROUND

	1.1
	Certain
inventions characterized as the PEREGRINE(TM) Dose Calculation System ("Inventions") and certain copyrightable works characterized as the computer program PEREGRINE(TM)
version 1.1 ("Software"), described in LLNL patents, patent applications and copyrights listed in Exhibit A (LICENSED PATENTS AND LICENSED COPYRIGHTS), which may be useful for various radiation
therapy applications, were made at LLNL and are covered by THE REGENTS' Patent Rights and THE REGENTS' Copyright Rights as defined in Article 2 (DEFINITIONS).

	1.2
	LLNL
published a Commerce Business Daily announcement in which it sought one or more industrial partners to commercialize the PEREGRINE(TM) Dose Calculation System as a means of
achieving LLNL's objective of ubiquitous, rapid distribution of PEREGRINE(TM) to radiation therapy clinics. NOMOS Corporation responded to LLNL's announcement and shares
LLNL's objective in commercializing the PEREGRINE(TM) Dose Calculation System. NOMOS Corporation Radiation Treatment Planning

	1.3
	NOMOS
Corporation entered into a Mutual Nondisclosure Agreement provided in Exhibit D (MUTUAL NONDISCLOSURE AGREEMENT), which is incorporated herein, that allowed it to
evaluate its interest in taking a license to the Inventions and Software.

	1.4
	NOMOS
Corporation is interested in acquiring certain rights to the Inventions and Software for the development, manufacture, and sale of products and services based on the Inventions
and Software. In addition to selling directly to its customers, NOMOS Corporation is willing to sell such products on an OEM basis or to sublicense Inventions and Software to other companies,
including NOMOS Corporation's competitors, to facilitate ubiquitous, rapid distribution of the PEREGRINE(TM) Dose Calculation System.

	1.5
	THE
REGENTS is willing to grant such rights so that the Inventions and Software may be developed and used to the fullest extent for the benefit of the Unites States' economy and the
general public.

	1.6
	NOMOS
Corporation recognizes that royalties due under this Agreement will be paid on licensed patent applications, issued patents, and copyrights.

	1.7.
	The
Parties have entered into a Work for Others agreement to facilitate transfer of the PEREGRINE(TM) Dose Calculation System to NOMOS Corporation for commercial development and to
further develop the Inventions and Software.

	1.8
	NOMOS
Corporation is a "small entity" as defined in 37 CFRss.1.9.

	1.9
	NOMOS
Corporation is a "small business firm" as defined at section 2 of Pub. L. 85-536 (15 U.S.C.ss.632). 

1

 

THEREFORE,
the Parties agree as follows: 

	2.
	DEFINITIONS

	2.1
	"Effective
Date" means the date of execution by the last signing Party.

	2.2
	"Field
of Use" is the application or use defined in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS).

	2.3
	"Government"
means the United States Government.

	2.4
	"Lease
Price" means gross income from a contract by which LICENSEE or its sublicensees conveys Licensed Products for a specified term at a specified fee.

	2.5
	"Licensed
Methods" are any methods, procedures, processes, or other subject matter whose use or practice would constitute an infringement of THE REGENTS' Patent Rights but for the
license granted to LICENSEE under this Agreement.

	2.6
	"Licensed
Patents" are:

	2.6.1
	U.S.
patents and U.S. patent applications specified in Exhibit A (LICENSED PATENTS AND LICENSED COPYRIGHTS), and U.S. patents resulting from these applications and
continuations of these applications, including divisionals resulting from these applications, but not including continuation-in-part applications resulting from these
applications;

	2.6.2
	reissues
of 2.6.1;

	2.6.3
	foreign
patent applications filed under Article 11 (PATENT PROSECUTION AND MAINTENANCE) and patents resulting from these applications; and,

	2.6.4
	Licensable
WFO Subject Inventions.

	2.7
	"Licensed
Products" are products that 1) incorporate or are produced by the practice of subject matter claimed in Licensed Patents, and whose manufacture, use, sale, import, or
offer for sale would constitute an infringement of THE REGENTS' Patent Rights, or 2) duplicate, display, perform, or are Derivative Works of the subject matter of Licensed Copyrights and whose
duplication, distribution, display, or performance would constitute an infringement of Licensed Copyrights, but for the license granted to LICENSEE under this Agreement.

	2.8
	"LICENSEE"
means NOMOS Corporation.

	2.9
	"Net
Sales," as used in this Agreement to compute royalties, means the aggregate Sale Price, Lease Price, and Service Price of Licensed Products and Licensed Methods by LICENSEE and
any sublicensees in transactions throughout the world with independent third parties for cash, or other consideration as mutually agreed by the Parties, using generally accepted accounting principles.

	

	No
deductions will be made from Net Sales for commissions paid to individuals whether they are with independent sales agencies or regularly employed by LICENSEE and on its
payroll, or for cost of collections.

	2.10
	"Sale
Price" means the gross invoice selling price after deducting:

	2.10.1
	Discounts
allowed in amounts customary in the trade;

	2.10.2
	Sales,
tariff duties or use taxes directly imposed and with reference to particular sales;

	2.10.3
	Allowances
actually paid and limited to rejections, returns, and prompt payment and volume discounts granted to customers of Licensed Products, whether in cash or Licensed Products
in lieu of cash;

	2.10.4
	Freight,
transport packing, insurance charges associated with transportation; and 

2

 

	2.10.5
	Taxes,
tariff, or import/export duties based on sales when included in gross sales, but not value-added taxes or taxes assessed on income derived from such sales.

	

	The
Sale Price of Licensed Products and Licensed Methods that are disposed of other than by sale or lease is LICENSEE'S gross invoice selling price for products of similar
kind and quality, sold in similar quantities provided that the Sale Price shall not be less than the minimum value established in section C.2 of Exhibit C (FEES AND ROYALTIES). If
LICENSEE is not currently offering comparable products for sale, then the Sale Price is the average gross invoice selling price at which products of similar kind and quality, sold in similar
quantities, are currently offered for sale by other manufacturers. If comparable products are not currently sold or offered for sale by others, then the Sale Price will be LICENSEE'S cost of
manufacture, determined by LICENSEE'S customary accounting procedures, plus LICENSEE'S standard markup.

	2.11
	"Sales
of Licensed Products" means sale or lease of Licensed Products or performance of services using Licensed Products, Licensed Methods or Licensed Copyrights.

	2.12
	"Service
Price" means gross income from services performed by LICENSEE or its sublicensees using Licensed Products, Licensed Methods, or Licensed Copyrights, including gross income
for support, maintenance, and repair services.

	2.13
	"THE
REGENTS' Patent Rights" are THE REGENTS' rights in Licensed Patents under applicable patent laws.

	2.14
	"THE
REGENTS' Copyright Rights" means THE REGENTS' rights in Licensed Copyrights under applicable copyright laws.

	2.15
	"Licensed
Copyrights" means the copyrighted works listed in Exhibit A (LICENSED PATENTS AND LICENSED COPYRIGHTS) and Licensable WFO Computer Software.

	2.16
	"Derivative
Work" means a work that is based on one or more pre-existing works and that, if reproduced, distributed to the public, or displayed publicly or performed
publicly without permission of the owner of the pre-existing work, would constitute copyright infringement.

	2.17
	"Licensable
WFO Subject Inventions" means Contractor's Subject Inventions arising from the WFO to which rights have been waived to THE REGENTS by DOE for licensing in accordance with
THE REGENTS' Contract No. W-7405-ENG-48 with DOE.

	2.18
	"WFO"
means Work for Others Agreement No. L-8788 by and between the Parties.

	2.19
	Licensable
WFO Computer Software" means Contractor's Computer Software arising from the WFO in which the Contractor has been given permission to assert copyright in accordance with
its prime contract with DOE.

	2.20
	"Use
Sublicense" means any agreement by LICENSEE or a sublicensee which grants to end users, only the right to use, on a single computer or compute server, object code versions of
Licensed Products.

	3.
	LICENSE
GRANT

	3.1
	The
license rights granted to LICENSEE by THE REGENTS are set forth in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS).

	3.2
	The
Government retains a paid-up, royalty-free, nontransferable, worldwide, irrevocable license to practice Licensed Patents by or on behalf of the Government.
The Government has certain other rights under 35 U.S.C.ss.ss.200-212 and applicable regulations. 

3

 
	3.3
	The
Government retains for itself and others acting on its behalf a paid-up, royalty-free, worldwide, irrevocable license in Licensed Copyrights to reproduce,
prepare Derivative Works, and perform publicly and display publicly. Beginning ten (10) years after January 14, 1999, subject to possible five-year renewals, the Government
is granted for itself and others acting on its behalf a paid-up, nonexclusive, irrevocable worldwide license in Licensed Copyrights to reproduce, prepares, distribute copies to the public,
perform publicly and display publicly, and to permit others to do so.

	3.4
	THE
REGENTS reserves all rights not otherwise granted in this Agreement and the right to use THE REGENTS' Patent Rights and THE REGENTS' Copyright Rights for educational and research
purposes.

	4.
	SUBLICENSING
RIGHTS AND OBLIGATIONS

	4.1
	The
sublicensing rights granted to LICENSEE by THE REGENTS are set forth in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS), Paragraph B.2.

	4.2
	LICENSEE
will provide THE REGENTS with an executed copy of each sublicense within thirty (30) days of execution of the agreement.

	4.3.
	LICENSEE
must include in any sublicense all the rights and obligations due THE REGENTS and the Government set forth in this Agreement.

	4.4
	LICENSEE
will promptly forward to THE REGENTS any reports and statements it receives from sublicensees under Article 4.3.

	4.5
	LICENSEE
must include in all sublicenses the notice that upon termination of this Agreement for any reason, THE REGENTS will automatically succeed to all rights of LICENSEE arising
from sublicenses granted under this Agreement.

	5.
	FEES,
ROYALTIES AND PAYMENTS

	5.1
	As
partial consideration for rights granted to LICENSEE, LICENSEE will pay to THE REGENTS a license issue fee and maintenance fees as set forth in Exhibit C (FEES AND
ROYALTIES).

	5.2
	As
further consideration for rights granted to LICENSEE, LICENSEE will pay to THE REGENTS a minimum annual royalty and an earned royalty based on Net Sales as set forth in
Exhibit C (FEES AND ROYALTIES).

	5.3
	LICENSEE
will pay royalties to THE REGENTS according to the schedule specified in Article 7 (PROGRESS AND ROYALTY REPORTS).

	5.4
	LICENSEE
will pay all fees and royalties in U.S. dollars collectible at par in San Francisco, California. When Licensed Products are sold for currencies other than U.S. dollars,
earned royalties will first be determined in the foreign currency of the country in which the Licensed Products were sold and then converted into equivalent U.S. dollars. The exchange rate is that
rate quoted in the Wall Street Journal on the last business day of the reporting period and is quoted as local currency per U.S. dollar. LICENSEE will be responsible for all bank transfer charges.

	5.5
	Notwithstanding
the provisions of Article 26 (FORCE MAJEURE), if at any time legal restrictions would prevent LICENSEE from making payment of part or all of any royalties in
any country outside the U.S. from LICENSEE'S source of funds outside the U.S., LICENSEE will convert the amount owed to THE REGENTS into U.S. funds and pay THE REGENTS directly from LICENSEE'S U.S.
source of funds.

	5.6
	No
royalties are due on Net Sales to the Government. LICENSEE will reduce the amount charged for such sales by an amount equal to the royalty otherwise due THE REGENTS. 

4

 
	6.
	PERFORMANCE
OBLIGATIONS

	6.1
	LICENSEE,
upon execution of this Agreement, will diligently proceed with development, regulatory approvals, manufacture, and sale of Licensed Products and use of Licensed Methods, and
earnestly and diligently endeavor to market the same as specified in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS).

	6.2
	During
the term of this Agreement, LICENSEE will demonstrate a continuing effort to commercialize and sell Licensed Products and use Licensed Methods to meet market demand.

	6.3
	If
LICENSEE does not meet the performance obligations specified in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS), THE REGENTS may at its sole option:
(a) convert the limited exclusive license for Licensed Patents and Licensed Copyrights to a nonexclusive license; (b) negotiate with LICENSEE a new schedule and conditions for
continuation of a limited exclusive license; or (c) terminate this Agreement.

	6.4
	THE
REGENTS will notify LICENSEE if THE REGENTS is approached by a third party seeking a license to make, use, or sell Licensed Products in LICENSEE'S Field of Use. LICENSEE will
negotiate in good faith with that third party to grant a sublicense for any Licensed Patents or Licensed Copyrights in the market for which LICENSEE and existing sublicensees are not meeting
commercial demand. The determination to grant a sublicense may be based on LICENSEE'S business interests. LICENSEE will provide THE REGENTS with justification for denying any such sublicense.

	6.5
	During
the term of this Agreement, LICENSEE will conduct normal, continuous business operations. If LICENSEE seeks protection under any United States bankruptcy proceedings during the
term of this Agreement, LICENSEE will notify THE REGENTS in writing no later than seventy-two (72) hours after the bankruptcy filing. THE REGENTS has the option to terminate this
Agreement upon a bankruptcy filing by the LICENSEE. 

5

  

	7.
	PROGRESS
AND ROYALTY REPORTS

	7.1
	SEMI-ANNUAL
PROGRESS REPORT: LICENSEE will submit to THE REGENTS semiannual progress reports according to the following schedule: 

	Due Date
 
	 	For Previous Period

	February 28	 	July I - December 31
	August 31	 	January 1 - June 30

	

	The
progress report must cover LICENSEE'S activities in meeting the performance obligations set forth in Article 6 (PERFORMANCE OBLIGATIONS) and Exhibit B
(RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS), and must include at a minimum the following information: 

Name of LICENSEE  

 
 

License Number    
    

 
 

Date of Report    
    

 
 

Reporting period    

 
 

Summary of work completed    

 
 

Summary of work in progress    

	

	Current
schedule of anticipated events or milestones

	

	Description
of Licensed Products or Licensed Methods under development

	

	Licensed
Patents and Licensed Copyrights practiced or incorporated into each Licensed Product and Licensed Method under development Anticipated market introduction date of
Licensed Products /Methods 

 
 

Commercial name of Licensed Products /Methods    
    

	

	A
summary of resources (dollar value) spent in the reporting period on commercialization efforts

	

	Name
and summary of activities of sublicensees, if any

	

	Changes
in corporate ownership (see Article 18, ASSIGNABILITY)

	

	Change
in small entity status (see Article 1, BACKGROUND)

	

	Addition
of and/or participation in an affiliate

	

	Existence
of and/or participation in a joint venture

	7.2
	FIRST
COMMERCIAL SALE: Within thirty (30) days following the first commercial sale of each type of Licensed Product in the U.S. and each country outside the U.S. by LICENSEE,
LICENSEE will report to THE REGENTS, at a minimum, the following information:

License Number

Name of LICENSEE

6

 

Date
of Report

Date of First Commercial Sale or Lease

Place of First Commercial Sale or Lease

Description of Licensed Products/Methods sold or leased

Licensed Patents and Licensed Copyrights practiced or incorporated 

	7.3
	QUARTERLY
WRITTEN ROYALTY REPORTS: After the First Commercial Sale of Licensed Products or Licensed Methods anywhere in the world by LICENSEE, LICENSEE will submit quarterly written
royalty reports to THE REGENTS as follows: 

	Due Date
 
	 	For Previous Period

	February 28	 	October I-December 31
	May 31	 	January 1-March 31
	August 31	 	April I-June 30
	November 30	 	July I-September 30

	

	If
LICENSEE has not sold or used any Licensed Products or Licensed Methods during the reporting period, LICENSEE will so state in the royalty report. The quarterly royalty
report must include at a minimum the following information: License Number Name of LICENSEE Date of Report Reporting period Report of sales: For each type of Licensed Products/ Methods: 

 
  Name/ description of each type of product or process    

	

	A.
Domestic sales:

1. Description of Licensed Products /Methods

2. Unit price (sale, lease, and/or use)

3. Units sold in U.S.

4. Units leased in U.S.

5. Gross sales in U.S.

6. Net Sales in U.S.

7. Accrued royalties

8. If Government approval requirements apply to sale/use of the Licensed Product/Method (see Article 24,

GOVERNMENT APPROVAL OR REGISTRATION), provide details. B. Foreign sales:

1. Country of sales

2. Description of Licensed Products /Methods

3. Unit price (sale, lease, and/or use)

4. Units sold in each country

5. Units leased in each country

6. Gross sales in each country

7. Net Sales in each country

8. Monetary exchange rate

9. Accrued royalties in $U.S.

10. If foreign government approval/ registration requirements apply to sale/use of the Licensed Product/Method (see Article 24, GOVERNMENT APPROVAL OR REGISTRATION), provide details.

C. Government Sales:

1. Description of Licensed Products /Methods

2. Unit price (sale, lease, and/or use)

3. Units sold

4. Units leased

5. Gross sales

6. Net Sales to the Government 

7

 
	

	Provide
information A-C for each type of product or process sold 

 
 

D. Royalties Due THE REGENTS    
    

	

Minimum Royalty Paid

for this Calendar Year
	 	Total Accrued Royalties

to Date

for this Calendar Year
	 	

Royalties Due

       

 

	7.4
	LICENSEE
will provide THE REGENTS with an annual audited statement of royalty accounts within sixty (60) days after the end of each calendar year. THE REGENTS will protect such
statements as Proprietary Information and not disseminate them unless required by law.

	7.5
	LICENSEE
will report in writing to THE REGENTS, within ten (10) days of their occurrence, dates of the following events pertaining to performance obligations specified in
Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS):

	7.5.1
	LICENSEE'S
filings of relevant regulatory applications pertaining to Licensed Products in accordance with B.5.1.

	7.5.2
	Each
grant of clearance by the FDA for Licensed Products.

	7.5.3
	LICENSEE'S
compliance with performance obligations specified in B.5.2, B.5.4, B.5.5, B.5.6, and B.5.7.

	8.
	BOOKS
AND RECORDS

	8.1
	LICENSEE
will keep books and records accurately showing the manufacture, use, sale, and lease of Licensed Products, Licensed Methods and Licensed Copyrights, and Sales of Licensed
Products under this Agreement. LICENSEE will preserve such books and records for at least five (5) years after the date of the royalty payment to which they apply. Such books and records will
be open for inspection by representatives or agents of THE REGENTS at all reasonable times, with reasonable notice given.

	8.2
	THE
REGENTS will pay the costs incurred by its representatives or agents to examine LICENSEE's books and records. If there is an error adverse to THE REGENTS in LICENSEE'S royalty
accounting, then LICENSEE will pay THE REGENTS within ten (10) days the amount necessary to correct such error. If there is an error adverse to THE REGENTS in LICENSEE'S royalty accounting of
more than ten percent (10%) of the total royalties due for any year, then LICENSEE will pay the costs incurred by THE REGENTS' representatives and agents for such examination.

	8.3
	LICENSEE
will provide THE REGENTS with an annual audited financial statement of LICENSEE, including at a minimum a balance sheet and operating statement or LICENSEE'S annual report.
Such statement will be due to THE REGENTS within one hundred twenty (120) days following the close of LICENSEE'S fiscal year to which such statement relates.

	9.
	TERM

	9.1
	The
term of this Agreement is the longer of either the term of the license to Licensed Patents or the term of the license to Licensed Copyrights.

	9.2
	The
term of the license to Licensed Patents will commence on the Effective Date and, unless terminated by operation of law or by acts of the Parties under this Agreement, will remain
in effect until the expiration or abandonment of all Licensed Patents. 

8

 
	9.3
	The
term of the license to Licensed Copyrights will commence on the Effective Date and, unless terminated by operation of law or by acts of the Parties under this Agreement, will
remain in effect for ten (10) years from January 14, 1999, the date on which THE REGENTS received permission to assert copyright. The term of the license to Licensed Copyrights may be
renewed for additional five-year periods for the life of the copyright upon mutual written agreement of the Parties.

	10.
	TERMINATION
AND DISPOSITION OF LICENSED PRODUCTS

	10.1
	If
LICENSEE fails to perform any material term or covenant of this Agreement, THE REGENTS may give written notice to LICENSEE that if LICENSEE has not cured such failure within sixty
(60) days after the effective date of receipt of the notice, this Agreement will terminate at the end of such sixty-(60) day period or at the end of such longer period as may be set
forth in THE REGENTS' notice.

	10.2
	LICENSEE
may terminate this Agreement by giving at least thirty (30) days prior written notice to THE REGENTS.

	10.3
	Termination
of this Agreement will not relieve LICENSEE of any obligation or liability accrued hereunder prior to such termination, nor rescind any payments due or paid to THE
REGENTS prior to the time such termination becomes effective. Such termination will not affect, in any manner, any rights of THE REGENTS arising under this Agreement prior to such termination. Any and
all obligations of the Parties under this Agreement will remain in effect until properly fulfilled or otherwise discharged, notwithstanding the completion or early termination of this Agreement.

	10.4
	Within
thirty (30) days after termination of this Agreement by either Party, LICENSEE will provide THE REGENTS with a written inventory of all Licensed Products in process of
manufacture or in stock on the date of termination. LICENSEE may complete Licensed Products in the process of manufacture at the time of termination, and may dispose of Licensed Products for sixty
(60) days after the date of termination provided that LICENSEE pays royalties to THE REGENTS on such dispositions. At the conclusion of the sixty (60) day period, LICENSEE will destroy
any remaining Licensed Products in stock or in process of manufacture and certify such destruction to THE REGENTS.

	10.5
	LICENSEE
may not practice Licensed Patents or use Licensed Copyrights after the date of termination of this Agreement except as necessary to complete the manufacture of Licensed
Products as permitted under Article 10.4.

	10.6
	This
Agreement will terminate, effective thirty (30) days after the Effective date of notice by THE REGENTS, if LICENSEE ceases to carry on its business.

	11.
	PATENT
PROSECUTION AND MAINTENANCE

	11.1
	THE
REGENTS will prosecute U.S. patent applications and maintain U.S. patents licensed under this Agreement at THE REGENTS' expense, unless otherwise agreed by the Parties.

	11.2
	LICENSEE
may request foreign rights in Licensed Patents, if such rights are available. Unless requested herein, LICENSEE must request in writing such rights, and specify the
countries in which it wants rights, within seven (7) months after the filing date of the U.S. applications. Failure to request such rights will be considered an election not to seek foreign
rights. THE REGENTS may file patent applications at its own expense in any country in which LICENSEE has not elected to secure foreign rights, and LICENSEE has no rights to any such foreign
applications and resultant patents. 

9

 
	11.3
	LICENSEE
will pay all costs, including those incurred by THE REGENTS prior to the Effective Date, associated with preparation, filing, prosecution, and maintenance of Licensed
Patents in foreign countries in which LICENSEE obtains rights under this Agreement. All Licensed Patents will be held in the name of THE REGENTS and obtained using counsel selected by THE REGENTS.

	11.4
	LICENSEE
may terminate its license to foreign patent applications or patents, and its obligation to pay any further costs for those foreign rights, upon ninety (90) days
written notice to THE REGENTS. THE REGENTS or the Government may, at its sole discretion and expense, continue prosecution and/or maintenance of any patents or applications for which LICENSEE has
relinquished rights.

	12.
	PATENT
AND COPYRIGHT INFRINGEMENT

	12.1
	If
LICENSEE learns of the possible infringement by a third party of any Licensed Patents or Licensed Copyrights, LICENSEE will inform THE REGENTS in writing within thirty
(30) days and provide all known evidence of the infringement. LICENSEE will not contact such third party concerning the infringement without prior written approval of THE REGENTS. The Parties
will use their best efforts to terminate such infringement without litigation.

	12.2
	LICENSEE
may request in writing that THE REGENTS take legal action against an infringer of any Licensed Patents or Licensed Copyrights, which request must include reasonable evidence
of the infringement and of potential damages to LICENSEE. Within one hundred (100) days after the date of receipt by THE REGENTS of LICENSEE'S request, if the infringement continues, THE
REGENTS will notify LICENSEE in writing that THE REGENTS will either:

	12.2.1
	Commence
suit on its own account; or

	12.2.2
	Refuse
to participate in such suit. LICENSEE may thereafter bring suit for infringement at its own expense if, and only if, THE REGENTS elects not to commence suit and if the
infringement occurred during the period and in a jurisdiction where LICENSEE has exclusive rights under this Agreement. However, in the event LICENSEE elects to bring suit in accordance with this
Article, THE REGENTS may thereafter join such suit at its own expense. If THE REGENTS elects to not participate in such suit, LICENSEE may join THE REGENTS in any suit in which THE REGENTS is a
necessary party for the suit to proceed, and if so joined the LICENSEE will pay all reasonable costs of THE REGENTS associated with joining the suit as a necessary party to the litigation.

	12.3
	Any
legal or equitable action brought under this Article 12 will be at the expense of the Party bringing such legal or equitable action and all recoveries will belong to such
Party. Legal or equitable action brought jointly by THE REGENTS and LICENSEE and participated in by both will be at the joint expense of the Parties in such proportions as are agreed to in writing,
and all recoveries will be shared by them in proportion to the expense paid by each Party, or otherwise as they may agree in writing.

	12.4
	The
Parties will cooperate with each other in legal and equitable proceedings instituted against an infringing third party, but such cooperation by a Party will be at the expense of
the Party bringing such legal or equitable action; if both Parties bring the action, the principles of Article 12.3 will apply. Such legal or equitable action will be controlled by the Party
bringing the legal or equitable action, except that THE REGENTS may be represented by counsel of its choice in any action brought by LICENSEE.

	13.
	USE
OF NAMES AND TRADEMARKS

	

	Neither
Party has any right to use any name, trade name, trademark, or other designation of the other Party (including any contraction, abbreviation, or simulation) in
advertising, publicity, or 

10

 

other
promotional activities. Unless required by law, the use of the name "Lawrence Livermore National Laboratory," or "The Regents of the University of California," or the name of any University of
California campus by LICENSEE is expressly prohibited under California Education Code ss.92000. 

	14.
	LIMITED
WARRANTY

	14.1
	THE
REGENTS has the right to grant the license granted in this Agreement.

	14.2
	THIS
LICENSE AND THE ASSOCIATED INVENTIONS AND SOFTWARE ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR
IMPLIED. THE REGENTS AND DOE MAKE NO REPRESENTATION OR WARRANTY THAT LICENSED PRODUCTS OR LICENSED METHODS WILL NOT INFRINGE ANY PATENT, COPYRIGHT OR OTHER PROPRIETARY RIGHT.

	14.3
	IN
NO EVENT WILL THE REGENTS OR DOE BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR THE USE OF THE SOFTWARE, INVENTIONS,
LICENSED METHODS, OR LICENSED PRODUCTS.

	14.4
	Nothing
in this Agreement will be interpreted as:

	14.4.1
	A
warranty or representation by THE REGENTS as to the validity or scope of Licensed Patents or Licensed Copyrights; or

	14.4.2
	A
warranty or representation that anything made, used, duplicated, displayed, performed, sold, or otherwise disposed of under the license granted in this Agreement is or will be
free from infringement of intellectual property rights of third parties; or

	14.4.3
	Any
obligation to bring suit against a third party for patent or copyright infringement; or

	14.4.4
	Conferring
by implication, estoppel, or otherwise any license or rights under 1) any patents of THE REGENTS other than Licensed Patents, regardless of whether such patents
are dominant or subordinate to Licensed Patents or 2) any copyrights of THE REGENTS other than Licensed Copyrights as defined in this Agreement; or

	14.4.5
	An
obligation to furnish to LICENSEE or any third party any know-how, improvements, or Derivative Works not specifically provided in this Agreement. 

11

  

	15.
	INDEMNIFICATION

LICENSEE
will, and will require its sublicensees to, indemnify, hold harmless, and defend THE REGENTS, DOE, their officers, employees, and agents; the sponsors of the research that led to the
Inventions and Software; and the inventors and authors against any claims, suits, losses, liabilities, damages, costs, fees, and expenses resulting from or arising out of exercise of this license or
any sublicense. LICENSEE will pay any and all costs, including reasonable attorney fees, incurred by THE REGENTS in enforcing this indemnification. 

	16.
	INSURANCE

	16.1
	LICENSEE
will insure its activities relating to this Agreement at its own cost with an insurance company acceptable to THE REGENTS. LICENSEE will obtain, keep in force, and maintain
insurance as follows with an insurance company acceptable to THE REGENTS or an equivalent program of self-insurance: Comprehensive or Commercial Form General Liability Insurance, including
contractual liability and product liability, with coverage as follows:

	16.1.1
	Each
occurrence coverage of not less than One Million Dollars ($1,000,000.00);

	16.1.2
	Product
Liability Insurance: completed operations aggregate coverage of not less than Ten Million Dollars ($10,000,000.00);

	16.1.3
	Personal
and Advertising Injury: coverage of not less than One Million Dollars ($1,000,000.00); and

	16.1.4
	General
Aggregate (Commercial Form Only): coverage of not less than Five Million Dollars ($5,000,000.00). 

These
coverages do not limit the liability of LICENSEE to THE REGENTS in any way. LICENSEE will provide THE REGENTS, upon request, with certificates of insurance or self-insurance,
including renewals that show compliance with these requirements. LICENSEE'S failure to maintain such required insurance will be considered a material breach of this Agreement. 

	16.2
	If
the required insurance is written on a claims-made form, coverage must provide a retroactive date of placement before or coinciding with the Effective Date of this
Agreement.

	16.3
	LICENSEE
will maintain the general liability insurance specified in this Article16 during the period that the Licensed Patents or Licensed Copyrights are being used and/or Licensed
Products are being sold or otherwise commercially distributed by LICENSEE, and for a period of not less than five (5) years thereafter.

	16.4
	LICENSEE'S
insurance coverage must:

	16.4.1
	Provide
for at least thirty (30) days advance written notice to THE REGENTS of cancellation or any modification;

	16.4.2
	Indicate
that DOE, THE REGENTS, and their respective officers, employees, students, and agents, are endorsed on the policy as additional named insureds; and

	16.4.3
	Include
a provision that the coverage is primary and does not participate with, or is in excess of, any valid and collectible insurance, program, or self-insurance
carried or maintained by THE REGENTS.

	17.
	WAIVER

	17.1
	No
provision of this Agreement is deemed waived and no breach excused unless such waiver or consent is made in writing and signed by the Party to have waived or consented. 

12

 
	17.2
	Failure
on the part of either Party to exercise or enforce any right of such Party under this Agreement will not be a waiver by such Party of any right, or operate to bar the
enforcement or exercise of the right at any time thereafter.

	18.
	ASSIGNABILITY

This
Agreement is binding on and inures to the benefit of THE REGENTS, its successors and assigns, but is personal to LICENSEE. Any assignment or bankruptcy assumption of this Agreement requires prior
written consent of THE REGENTS which consent shall not be unreasonably withheld. 

	19.
	LATE
PAYMENTS 

If
THE REGENTS does not receive payments or fees due from LICENSEE hereunder when due, LICENSEE must pay such payments or fees within sixty (60) days plus interest charges at the rate of ten
percent (10%) simple interest per annum from the date on which the payment was originally due, or THE REGENTS may terminate this Agreement in accordance with its terms. 

	20.
	NOTICES 

Any
report, payment, notice, or other communication that either Party receives under this Agreement must be in writing and will be properly given and effective on the date of delivery if delivered in
person (including delivery by courier service), or the fifth (5th) day after mailing if mailed by first-class certified mail, postage paid, to the addresses given below (or to an address designated by
written notice to the other Party), or the date of facsimile with confirmed receipt. 

	In the case of LICENSEE:	 	NOMOS Corporation

2591 Wexford-Bayne Road

Sewickley, PA 15143

Phone: (724) 934-8200

Fax: (724) 934-5488

Attention: President
	In the case of THE REGENTS:	 	 
	All correspondence, original progress reports, and royalty reports:	 	Lawrence Livermore, National Laboratory

Industrial Partnership and Commercialization

P.O. Box 808, L-795

7000 East Ave., L-795

Livermore, CA 94550

Attention: Director, IPAC

Fax: (925) 423-8988
	Payments and copies of corresponding royalty reports:	 	Lawrence Livermore National Laboratory

P.O. Box 5517 Livermore, CA 94550

	21.
	DISPUTES
AND GOVERNING LAWS 

The
Parties will attempt to jointly and promptly resolve any disputes arising from this Agreement. If the Parties are unable to resolve a dispute within a reasonable time from one Party's written
notice to the other that dispute resolution has begun, then either Party may commence proceedings in a court of competent jurisdiction. This Agreement will be governed by the laws of the State of
California, U.S.A., without regard to such State's conflict of laws provisions. 

	22.
	PATENT
MARKING 

LICENSEE
will mark all Licensed Products and their containers that are made, used, sold, or otherwise disposed of under this Agreement in accordance with applicable patent marking laws. 

13

 
	23.
	COPYRIGHT
MARKING 

For
all Licensed Products that incorporate Licensed Copyrights, LICENSEE will affix to all copies of such Licensed Products and their containers that are made, used, or sold or otherwise distributed
under this Agreement: 

	a)
	the
proper copyright notice in accordance with applicable copyright marking laws; and

	b)
	the
following notice: 

"NOTICE:
The Government is granted for itself and others acting on its behalf a paid-up, nonexclusive, irrevocable, worldwide license in this data to reproduce, prepare Derivative Works,
and perform publicly and display publicly. Beginning ten (10) years after January 14, 1999, and subject to any subsequent five (5) year renewals, the Government is granted for
itself and others acting on its behalf a paid-up, nonexclusive, irrevocable, worldwide license in this data to reproduce, prepare Derivative Works, distribute copies to the public, perform
publicly and display publicly, and to permit others to do so. NEITHER THE UNITED STATES NOR THE UNITED STATES DEPARTMENT OF ENERGY, NOR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, NOR ANY OF THEIR
EMPLOYEES, MAKES ANY WARRANTY, EXPRESS OR IMPLIED, OR ASSUMES ANY LEGAL LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS, OR USEFULNESS OF ANY INFORMATION, APPARATUS, PRODUCT, OR PROCESS
DISCLOSED, OR REPRESENTS THAT ITS USE WOULD NOT INFRINGE PRIVATELY OWNED RIGHTS." 

	24.
	GOVERNMENT
APPROVAL OR REGISTRATION 

If
this Agreement or any associated transaction is required by the law of any jurisdiction to be approved, permitted, or registered with any governmental agency, LICENSEE assumes all obligations to do
so. LICENSEE will notify THE REGENTS if LICENSEE becomes aware that this Agreement is subject to a United States or foreign government reporting, permitting, or approval requirement. LICENSEE will
make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting, permitting, or approval process. 

	25.
	EXPORT
CONTROL LAWS 

LICENSEE
will comply with all applicable United States and foreign laws and regulations concerning the transfer of Licensed Products and related technical data, including but not limited to
International Traffic in Arms Regulations (ITAR) and Export Administration Regulations. 

	26.
	FORCE
MAJEURE 

The
Parties will be excused from any performance required hereunder if such performance is rendered impossible or unfeasible due to any Acts of God, catastrophes, or other major events beyond their
reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lock-outs, or other serious labor
disputes; and floods, fires, explosions, or other natural disasters. However, either Party will have the right to terminate this Agreement pursuant to this Article upon sixty (60) days prior
written notice if either Party is unable to fulfill its obligations under this Agreement due to any of the causes mentioned above and such inability continues for a period of one (1) year. 

	27.
	UNITED
STATES PREFERENCE 

LICENSEE
agrees that any Licensed Products and Licensed Methods for applications, use, or sale shall be manufactured substantially in the United States. 

14

 
	28.
	PROPRIETARY
INFORMATION 

The
term of the Mutual Nondisclosure Agreement (MNDA) between the Parties, attached as Exhibit D (MUTUAL NONDISCLOSURE AGREEMENT), is hereby extended for the term of this Agreement. The
confidentiality obligation of the MNDA will also apply to any other Proprietary Information provided in connection with this Agreement that is clearly marked in accordance with the MNDA, such as
patent prosecution, engineering drawings, process and technical information, and other related information not contemplated when the MNDA was executed. 

	29.
	MISCELLANEOUS

	29.1
	The
headings of the Articles of this Agreement are for reference only and do not affect the interpretation of this Agreement.

	29.2
	Any
amendment or modification of this Agreement must be in writing and signed by each Party.

	29.3
	This
Agreement, with the attached Exhibits A, B, C, and D, embodies the entire understanding of the Parties with respect to the subject matter of this Agreement, and supersedes all
other communications, representations, or understandings, either oral or written, between the Parties with respect to such subject matter.

	29.4
	If
any provision of this Agreement is held to be invalid, illegal, or unenforceable in any respect, such provision will be enforced to the extent legally permissible and such
invalidity, illegality, or unenforceability will not affect any other provisions of the Agreement, and this Agreement will be construed as if the invalid, illegal, or unenforceable provision, or
relevant portion, were never in this Agreement.

	29.5
	Neither
Party is an agent of the other and neither will have any power to contract for or bind the other Party for any purpose. 

THE
REGENTS and LICENSEE hereby execute this Agreement, in duplicate originals, by their respective duly authorized officers. 

	NOMOS CORPORATION	 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
	

 	

 	
 	

LAWRENCE LIVERMORE NATIONAL LABORATORY
	

By:	

/s/ ANIL RASTOGI
 (Signature)	
 	

By:	

/s/ J. WADSWORTH
 (Signature)
	

Name:	

Anil K. Rastogi
	
 	

Name:	

Jeffrey Wadsworth

	

Title:	

President & CEO
	
 	

Title:	

Deputy Director for Science and Technology

	

Date Signed: 7/20/99	
 	

Date Signed: July 19, 1999

15

 
EXHIBIT A—LICENSED PATENTS AND LICENSED COPYRIGHTS  

THE LICENSED PATENTS ARE AS FOLLOWS:  

UNITED STATES PATENTS GRANTED:  

	Invention

Disclosure Number
 
	 	Patent

Number
	 	Title
	 	Inventors
	 	Filing

Date
	 	Issue

Date

	IL-9839	 	5870697	 	Calculation of Radiation Therapy Does Using all Particle Monte Carlo Transport	 	William P. Chandler, Christine L. Hartmann-Siantar, James A. Rathkopf	 	3/5/96	 	2/9/99

UNITED STATES PATENT APPLICATIONS:  

	Invention

Disclosure Number
 
	 	Patent

Number
	 	Title
	 	Inventors
	 	Filing

Date
	 	Issue

Date

	IL-10165	 	09/082511	 	Evaluated Teletherapy Source Library (ETSL)	 	Lawrence J. Cox, Alexis E. Schach von Wittenau	 	5/21/98	 	5/22/97
	IL-10350	 	09/238291	 	System and Method for Radiation Dose Calculation Within sub-Volumes of a Monte Carlo Based Particle Transport Grid	 	Paul M. Bergstrom, Thomas Daly, Edward I. Moses, Ralph Patterson, Dewey Garrett, Ronald House, Christine Hartmann-Siantar, Lawrence J. Cox, Donald H. Fujino, Alexis E. Schach Von Wittenau	 	1/28/99	 	11/12/98
	IL-10351	 	09/247651	 	FALCON: Automated Optimization for Arbitrary Criteria	 	Tser-Yuan Yang, Edward I. Moses, Christine L. Hartmann-Siantar	 	2/9/99	 	9/10/98

PROVISIONAL PATENT APPLICATIONS:  

	Invention

Disclosure Number
 
	 	Patent

Number
	 	Title
	 	Inventors
	 	Filing

Date

	IL-10472	 	60/123242	 	Correlated Histogram Representation of Monte Carlo Derived Medical Accelerator Photon-Output Phase Spaces	 	Alexis E. Schach von Wittenau	 	3/8/99

FOREIGN PATENTS GRANTED: None  

FOREIGN PATENT APPLICATIONS:  

	Invention

Disclosure Number
 
	 	Patent

Number
	 	Title
	 	Inventors
	 	Filing

Date

	IL-9839	 	97915859.9-EP

All EP

Countries	 	Calculation of Radiation Therapy Dose Using All Particle Monte Carlo Transport	 	William P. Chandler, Christine L. Hartmann-Siantar, James A. Rathkopf	 	3/5/96
	IL-9839	 	531993/1997-JP	 	Calculation of Radiation Therapy Does Using All Particle Monte Carlo Transport	 	William P. Chandler, Christine L. Hartmann-Siantar, James A. Rathkopf	 	2/28/97
	IL-9839	 	2248862-CA	 	Calculation of Radiation Therapy Does Using All Particle Monte Carlo Transport	 	William P. Chandler, Christine L. Hartmann-Siantar, James A. Rathkopf	 	2/28/97

16

  

FUTURE PATENT RIGHTS  

        Licensable WFO Subject Inventions will be added by amendment. THE LICENSED COPYRIGHTS ARE AS FOLLOWS: 

COPYRIGHT ASSERTION  

PEREGRINE(TM),
Version 1.1

1a.    Software Acronym:
 PEREGRINE.

	1b.
	Short
Title: 

        3D
All Particle Monte Carlo code to calculate radiation dose delivered to cancer patients. 

	2.
	Authors
Names and Affiliations: 

Paul
M. Bergstrom, William P. Chandler, Lila Chase, Larry J. Cox, Tom P. Daly, Don H. Fujino, Dewey. N. Garrett, Brian L. Guidry, Ron K. House, Don Y. Jong, Dave A. Knapp, Sarita S. May, Edward I.
Moses, Clark. L. Powell, James A. Rathkopf, Christine L. Hartmann Siantar, Alexis E. Schach von Wittenau, Rosemary S. Walling, Steve 1. Warshaw, Jody A White, (LLNL). 

	3.
	Software
completion Date: July 1999.

	4.
	Brief
Description: 

PEREGRINE
is a 3D All Particle Monte Carlo Code that calculates the dose to cancer patients from a variety of clinical radiation sources. PEREGRINE utilizes large nuclear, atomic, and electron
databases, the patient CT scan data, and the Monte Carlo method to accurately calculate the dose delivered to a patient for photon teletherapy sources. The results of the dose calculation are then
written to a file for graphical display over the CT scan data. 

	5.
	Method
of Solution: 

PEREGRINE
uses conventional analog and condensed history Monte Carlo radiation transport methods to calculate dose three-dimensional dose distributions in the body. It reads input from standard
treatment planning exchange files. 

	6.
	Computer(s)
for which software is written: 

UNIX
workstation. 

	7.
	Operating
System: 

UNIX,
Solaris. 

	8.
	Programming
Language(s) Used: 

Fortran
(physical transport), C (1/0), Perl (scripting language used to run PEREGRINE), Tcl/Tk (scripting and control). 

	9.
	Software
Limitations: 

Must
run on a UNIX workstation with >128MB RAM/CPU. 

	10.
	Unique
Features of the Software: 

PEREGRINE
package includes a PEREGRINE Monte Carlo transport software, LLNL generated atomic data. 

17

 
	11.
	Related
and Auxiliary Software: 

None. 

	12.
	Other
Programming or Operating Information or Restrictions: 

None.

	13.
	Hardware
Requirements: 

UNIX
workstation with >128MB RAM/CPU. 

	14.
	Time
Requirements: 

Time
requirements vary substantially with the complexity of the problem addressed. 

Technical Description of Licensed Copyrights  

        The files are: 

libpg—PEREGRINE
Monte Carlo library source files:

alias_sampling. F

alias_sampling_choice.F

check.F

direction_cosines.F

dose_mesh_data.F

electron_data.F

electron_physics.F

elpo_distribution.h

energy_groups.F

energy_groups.h

epsilon.h

file_io.F

form_factors.F

material_data.F

mesh_data.F

particle_attributes.h

particle_bank.F

particle_bank.h

particle_intercepts.F

pg_F pg_instantiate_device.F

pg_transport.F

photon_data.F

photon_physics.F

place_deposit.F

radial_function.F

random_numbers.F

random_numbers.h

source_data.F

source_electron_physics.F

source_geometry.F

source_particle.F

source_photon_physics.F

source_rejection.F

source_transport.F

18

 

timer.F
track_particle.F

transform_coordinates.F

transform_coordinates.h

version_pglib.h

libtpi—Treatment
Planning Interface source files: 

beam_geometry.c

ct_scan.c

dose.c

dose_array.c

f77_Wrapper.c

inst_log_file.c

log_msg.c

runtime_diagnostics.c

scanner_data.c

structurex

tpi_support.c

tpi_support.h

version.h

libtsl—Teletherapy
Source Library source files: 

beam_device_compare.c

crc_checksum.c

device_data.c

f77_wrapper.c

fit_data.c

fit_data.d

instantiate_device.c

modify_one_device.c

pdt_data.c

runtime_option.c

transform_one_device.c

tsl_support.c

tsl_support.h

include—source
files: 

case_data.h

distributed_data.h

histo.h

material_data.h

pdt_data.h

pg.h

pg_constants.h

pg_exec.h

pg_types. h

physics_constants_h

runtime_options.h

timer.h

tpi.h

tsl.h

tuning_parameters.h

19

 

Single-Threaded
test executive and utilities source files

Master Slave executive source files

FUTURE COPYRIGHT RIGHTS:  

        Licensable WFO Computer Software will be added by amendment. 

 
 

EXHIBIT B—RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS    
    

NOTICE

LICENSEE
CONSIDERS INFORMATION IN THIS EXHIBIT B TO BE PROPRIETARY. 

	B.1
	RIGHTS
GRANTED

	B.1.1
	Rights
to Licensed Patents 

Subject
to the limitations set forth in this Agreement, THE REGENTS hereby grants to LICENSEE an exclusive, nontransferable, royalty-bearing license to: a) make, have made, use, sell, offer for
sale, and import Licensed Products in the Field of Use, and b) practice Licensed Methods in the Field of Use. 

	B.1.2
	Rights
to Licensed Copyrights 

Subject
to the terms and conditions of this Agreement, THE REGENTS grants to LICENSEE an exclusive, nontransferable, royalty-bearing license to duplicate, display, perform, make Derivative Works,
distribute and have distributed, and sell Licensed Products covered by Licensed Copyrights in the Field of Use. 

	B.1.3
	"Field
of Use" means planning human and animal cancer therapies based on tumor irradiation with photons or electrons that are generated either by a radiation source external to the
patient (teletherapy) or by a radiation source internal to the patient (brachytherapy).

	B.2
	SUBLICENSING
RIGHTS 

THE
REGENTS also grants to LICENSEE the right to issue royalty-bearing sublicenses to third parties in the Field of Use, having rights no greater than those granted to LICENSEE, provided that LICENSEE
has exclusive rights inb such Licensed Patents and Licensed Copyrights in the Field of Use at the time of sublicensing. A Use Sublicense is considered to be a Licensed Product and not a sublicense as
contemplated in this B.2. 

	B.3
	RIGHTS
EXCLUDED 

Rights
that are not specifically granted in this Exhibit B or elsewhere in this Agreement are specifically excluded from the license. 

	B.4
	FUTURE
RIGHTS 

Licensable
WFO Subject Inventions and Licensable WFO Computer Software will be added to Exhibit A by amendment. 

	B.5
	PERFORMANCE
OBLIGATIONS

	B.5.1
	LICENSEE
will proceed diligently to develop, file relevant regulatory applications for and attempt to obtain relevant regulatory commercialization approvals with respect to the
manufacturing, marketing, and sale of Licensed Products for all uses in the Field of Use. LICENSEE will file with the U.S. Food and Drug Administration at least one 510k Application or PMA
(Pre-Market Approval) for clearance of Licensed Products for at least teletherapy uses within one (1) year of the Effective Date. Notwithstanding any other term of 

20

 

this
Agreement, for the purposes of (a) invoking/ complying with the Hatch-Waxman Act (35 U.S.C.ss.156) and any corresponding rules and regulations of the U.S. Patent & Trademark Office
regarding patent term extension, and (b)    seeking regulatory approval of LICENSEE'S Licensed Products and Licensed Methods, LICENSEE shall act as THE REGENTS' agent. To the extent deemed
necessary by LICENSEE, in good faith, the Parties will cooperate to secure regulatory approval of LICENSEE'S Licensed Products and Licensed Methods. 

	B.5.2
	LICENSEE
will release for distribution and offer Sales of Licensed Products by the later date of either October 1, 2000, or within sixty (60) days after the date of
FDA clearance for teletherapy uses of Licensed Products.

	
B.5.3
	LICENSEE
 will have gross revenues from Sales of Licensed Products or use of Licensed Methods of at least Three Million Dollars ($3,000,000.00) per calendar year, as measured at
the close of LICENSEE's business on 

December 31
of the relevant calendar year, commencing with the later of calendar year 2001, or the first full calendar year after a Licensed Product has been released for distribution and
offered for sale in accordance with paragraph B.5.2. 

	B.5.4
	LICENSEE
will release for distribution and offer first OEM sale of Licensed Products that interface with radiation treatment planning systems that are manufactured and sold, or
otherwise distributed to third parties, by entities other than LICENSEE by the later date of either 

October 1,
2001, or one year after initial release for distribution and offer of Sales of Licensed Products as defined in B.5.2. To the extent that some commercial entities may prefer to
sublicense Licensed Patents and Licensed Copyrights rather than to purchase Licensed Products on an OEM basis, LICENSEE'S sublicenses may satisfy this OEM performance obligation. 

	B.5.5
	LICENSEE
will release for distribution and offer first sale of Licensed Products in the Field of Use for brachytherapy by the later date of either October 1, 2002, or within
sixty (60) days after the date of FDA clearance for brachytherapy uses of Licensed Products.

	B.5.6
	LICENSEE
will release for distribution and offer first sale of Licensed Products in the Field of Use for inverse treatment planning by the later date of either October 1,
2002, or within sixty (60) days after the date of FDA clearance for inverse treatment planning uses of Licensed Products.

	B.5.7
	LICENSEE
will release for distribution and offer first sale of Licensed Products in the Field of Use for electron radiotherapy by the later date of either October 1, 2002, or
within sixty (60) days after the date of FDA clearance for electron radiotherapy uses of Licensed Products.

	B.5.8
	The
sales and other performance requirements specified above may, by mutual written consent of LICENSEE and THE REGENTS, be amended and/or extended at the written request of
LICENSEE to THE REGENTS, based upon legitimate business or technical reasons specified in reasonable detail in such written request. THE REGENTS will not unreasonably withhold its consent to requests
made in accordance with this paragraph.

	B.5.9
	ThefirstprogressreportwillbedueonFebruary28,2000.

B.6    OPTION RIGHT  

THE
REGENTS also grants to LICENSEE an option to negotiate terms under which THE REGENTS will add protons, neutrons or both particles to the Field of Use as otherwise defined in 

21

 

B.1.3
above (Option). The term of the Option will be eighteen (18) months from the Effective Date. LICENSEE may exercise this Option by providing THE REGENTS a written plan (Plan) for the
development and commercialization of Licensed Products in the expanded Field of Use (Expanded FOU) which Plan is acceptable to THE REGENTS. LICENSEE will provide the Plan as soon as practical, but in
no case later than fifteen (15) months after the Effective Date. Upon exercise of the Option, and acceptance of the Plan by THE REGENTS, THE REGENTS will negotiate in good faith terms for the
Expanded FOU. Terms will include, but not be limited by, specific performance obligations of LICENSEE pertaining to regulatory approvals and sales of Licensed Products in the Expanded FOU and
additional fees, royalties, or other compensation for the rights obtained by LICENSEE under the Option. 

EXHIBIT C—FEES AND ROYALTIES  

 NOTICE  

 LICENSEE CONSIDERS INFORMATION IN THIS EXHIBIT C TO BE PROPRIETARY.  

	C.1
	LICENSE
ISSUE FEE

	C.1.1
	As
partial consideration for this Agreement, LICENSEE will pay to THE REGENTS a nonrefundable issue fee of Three Hundred Thousand Dollars ($300,000.00) (License Issue Fee) as
follows:

	C.1.1.1
	Fifty
Thousand Dollars ($50,000.00) to be paid when LICENSEE executes the Agreement.

	C.1.1.2
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than October 1, 1999.

	C.1.1.3
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than November 1, 1999.

	C.1.1.4
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than December 1, 1999.

	C.1.1.5
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than January 1, 2000.

	C.1.1.6
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than February 1, 2000.

	C.1.2
	THE
REGENTS will execute the Agreement after receipt of LICENSEE'S executed copies of the Agreement and payment of the first installment of the License Issue Fee specified in
C.1.1.1 above.

	C.1.3
	The
License Issue Fee will not be credited against any other royalty or fee due from LICENSEE to THE REGENTS.

	C.1.4
	In
the event that LICENSEE grants sublicenses, LICENSEE will collect an issue fee equal to or greater than the License Issue Fee. LICENSEE will pay to THE REGENTS fifty percent
(50%) of any issue fee from sublicensing.

	C.2
	EARNED
ROYALTIES 

In
addition to the License Issue Fee, LICENSEE will pay THE REGENTS an earned royalty equal to eight percent (8%) of Net Sales by LICENSEE and any sublicensees. The earned royalty on sales of any
Licensed Product that is sold as part of a larger product system, shall be based on the average Net Sales of that Licensed Product sold separately on a non-OEM basis over the relevant
royalty reporting period. For the purposes of calculating earned royalties, the minimum value of any License Product shall be Fifty Thousand Dollars ($50,000.00) for the first two (2) full
years after the date of initial release for distribution and offer of Sales of Licensed Products as specified in B.5.2. The minimum value shall be Thirty-Five Thousand Dollars ($35,000.00)
for the next two (2) full years, and Twenty-Five Thousand Dollars ($25,000.00) thereafter. 

22

 

In
the event that LICENSEE terminates the WFO without cause and without funding sufficient to complete the tasks and deliverables specified in Phase I (Technology Transfer and Clinical Implementation)
of Attachment A to the WFO, the royalty rate specified above will be ten percent (10%). 

Payments
of earned royalties will be in accordance with the requirements of Article 4.2 (SUBLICENSING RIGHTS AND OBLIGATIONS), Article 5 (FEES, ROYALTIES AND PAYMENTS) and
Article 7 (PROGRESS AND ROYALTY REPORTS) of this Agreement. 

	C.3
	MAINTENANCE
FEES 

Beginning
in calendar year 2000, LICENSEE will pay THE REGENTS a license maintenance fee of Thirty Five Thousand Dollars ($35,000.00) per calendar year, which will be due according to the schedule in
CA. The maintenance fee in any calendar year will be creditable against the minimum annual royalty due in the same calendar year. 

	C.4
	MINIMUM
ANNUAL ROYALTIES 

LICENSEE
will pay to THE REGENTS a minimum annual royalty according to the requirements of Article 5 (FEES, ROYALTIES AND PAYMENTS) and the schedule below. Earned royalties paid to THE REGENTS
for Net Sales during a calendar year will be accrued and credited against the minimum annual royalty paid for that same calendar year. 

	Calendar Year
 
	 	Minimum Annual Royalty
	 	Due Date in Calendar Year

	2000	 	$	35,000.00	 	February 28
	2001	 	$	135,000.00	 	February 28
	2002	 	$	200,000.00	 	February 28
	2003	 	$	250,000.00	 	February 28
	2004	 	$	325,000.00	 	February 28
	2005 and thereafter for the life of this Agreement	 	$	400,000.00	 	February 28

EXHIBIT D—MUTUAL NONDISCLOSURE AGREEMENT  

23

QuickLinks

Exhibit 10.23

LIMITED EXCLUSIVE PATENT AND COPYRIGHT LICENSE AGREEMENT FOR PEREGRINE(TM) DOSE CALCULATION SYSTEM FOR RADIATION TREATMENT PLANNING BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND NOMOS CORPORATION LLNL
CASE NO. TL-1613-99 LAWRENCE LIVERMORE NATIONAL LABORATORY UNIVERSITY OF CALIFORNIA P.O. BOX 808, L-795, LIVERMORE, CA 94551 INDUSTRIAL PARTNERSHIPS AND COMMERCIALIZATION JULY 1999

TABLE OF CONTENTS

LIMITED EXCLUSIVE PATENT AND COPYRIGHT LICENSE AGREEMENT FOR PEREGRINE(TM) DOSE CALCULATION SYSTEM FOR RADIATION TREATMENT PLANNING

License Number

Date of Report

Reporting period

Summary of work completed

Summary of work in progress

Commercial name of Licensed Products /Methods

Name/ description of each type of product or process

D. Royalties Due THE REGENTS

EXHIBIT B—RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]